Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.52 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12150880 | 0.90 | ADORA2A (0.53) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL474846 | 0.90 | ADORA2A (0.53) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL12031227 | 0.90 | ADORA2A (0.53) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL12154572 | 0.90 | ADORA2A (0.53) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL12447020 | 0.88 | ADORA2A (0.51) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL730785 | 0.88 | ADORA2A (0.51) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL13650037 | 0.86 | ADORA2A (0.49) | ADORA2AADAADORA3PDE4DPDE3A | |
| SCHEMBL5481579 | 0.84 | ADORA2A (0.49) | ADORA2AADAADORA3PDE4DPDE3A | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL12149452 | 0.83 | ADORA2A (0.67) | ADORA2AADAADORA3PRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL13772636 | 0.83 | ADORA2A (0.67) | ADORA2AADAADORA3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADA 145/4885ADORA3 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.